The epidemiological programme is now complete, and, together with available other clinical and basic-science evidence, further supports the safety profile of insulin glargine as suggested earlier by its pharmacovigilance record (Diapedia)
Diabetes News Service
The epidemiological programme is now complete, and, together with available other clinical and basic-science evidence, further supports the safety profile of insulin glargine as suggested earlier by its pharmacovigilance record (Diapedia)
For iPhone and iPad | For Android devices
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
Website by Wired up Wales